---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-000028"
form_type: "8-K"
ticker: "OTLC"
cik: "0000908259"
company_name: "Oncotelic Therapeutics, Inc."
filed_at: "2025-01-02T23:59:59+00:00"
generated_at: "2026-05-28T19:19:56.033410+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Oncotelic extends reverse merger deadline with Mosaic ImmunoEngineering to June 30, 2025

## Summary
- Term sheet dated April 26, 2024, originally 90-day term, extended to Dec 31, 2024; now extended to June 30, 2025.
- No definitive agreement reached; extension allows continued due diligence and documentation.
- Both companies mutually agreed extension is in best interests; transaction remains conditional and not guaranteed.
- Extension letter executed December 31, 2024; no other term sheet modifications.

## SEC filing metadata
- accession: 0001493152-25-000028
- form_type: 8-K
- ticker: OTLC
- cik: 0000908259
- company_name: Oncotelic Therapeutics, Inc.
- filed_at: 2025-01-02T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/908259/000149315225000028/0001493152-25-000028-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/908259/000149315225000028/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-000028
- JSON: https://secwatch.observer/filing/0001493152-25-000028.json
- Plain text: https://secwatch.observer/filing/0001493152-25-000028.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.